Biosimilar Contract Manufacturing Market Size, Share, Trends & Forecast
The Biosimilar Contract Manufacturing Market is experiencing strong growth as pharmaceutical and biotechnology companies increasingly outsource the production of biosimilar medicines to specialized contract manufacturing organizations. Market Research Future estimates that the global market was valued at USD 7.73 billion in 2024 and is projected to reach USD 51.9 billion by 2035, registering a CAGR of 18.9% during 2025–2035.
Biosimilars are becoming increasingly important as healthcare systems seek cost-effective alternatives to expensive biological medicines. The expiration of patents for major biologic products is also creating opportunities for biosimilar developers and manufacturers.
Contract manufacturers can provide specialized facilities, technical expertise, process development, quality control, and commercial-scale production. This allows pharmaceutical companies to reduce capital requirements while accessing established manufacturing capabilities.